Always chasing the newest science, Schond Greenway joins MindMed; Mirati fills key vacancy with ex-Arena finance chief
From cell therapy to precision medicine, Schond Greenway has hopped from one burgeoning research area to the next throughout his career. Now he’s heading off to another: psychedelic therapy.
MindMed tapped Greenway as CFO on Monday, as CEO Robert Barrow guides the company through what he called “an exciting point in our growth.” The New York-based psychedelics company was the second to ever go public on an American exchange, behind Compass Pathways. And this year, Barrow’s lining up “numerous near-term milestones ahead across our pipeline.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.